Abstract: A composition can treat or prevent at least one physical state selected from the group consisting of oxidative stress, a condition associated with oxidative stress, a reduced level of glutathione, and a condition associated with a reduced level of glutathione. The composition contains an effective amount of a combination of at least one glycine or functional derivative thereof, at least one N-acetylcysteine or functional derivative thereof, and at least one nicotinamide riboside or NAD+ precursor. The composition can be orally administered, for example as one or more of a food product, a food for special medical purposes (FSMP), a nutritional supplement, a ready to drink formula, a dairy-based drink, a low-volume liquid supplement, powder formats for liquid reconstitution or a meal replacement beverage.
Type:
Grant
Filed:
September 26, 2019
Date of Patent:
May 7, 2024
Assignee:
Societe des Produits Nestle S.A.
Inventors:
Philipp Gut, Stephanie Blum-Sperisen, Giulia Lizzo
Abstract: Embodiments of the present invention provide solid oral dosage forms that upon daily administration to a subject provide plasma levels of decitabine with a 5-day AUC for decitabine that is equivalent to the 5-day AUC for a daily IV dose of decitabine of 20 mg/m2 administered as a one hour (1 h) infusion. Also provided according to embodiments of the present invention are solid oral dosage forms wherein upon daily administration to a subject provides a pharmacodynamic effect that is equivalent to the pharmacodynamic effect for a daily intravenous dose of decitabine of 20 mg/m2 administered as a one hour (1 h) infusion. Also provided are methods of treatment using a solid oral dosage form according to an embodiment of the invention.
Type:
Grant
Filed:
April 28, 2023
Date of Patent:
April 23, 2024
Assignee:
Otsuka Pharmaceutical Co., Ltd.
Inventors:
Aram Oganesian, Nipun Davar, Jim Hwaicher Kou
Abstract: The present invention is directed to compounds, compositions and methods for treating or preventing Zika virus. The compounds include pyrimidine and purine nucleosides and prodrugs thereof, including certain N4-hydroxycytidine nucleoside derivatives, sulfasalazine, and various entry inhibitors.
Type:
Grant
Filed:
March 22, 2017
Date of Patent:
April 23, 2024
Assignee:
Emory University
Inventors:
Raymond F. Schinazi, Franck Amblard, Bryan D. Cox, Leda Bassit, Longhu Zhou, Christina Gavegnano
Abstract: The present invention relates to a compound of Formula (I), or a stereoisomer, solvate, tautomer or pharmaceutically acceptable salt thereof, wherein X, W1, W2, Y, Z, R1, R2 and R3 are as defined in the disclosure herein, for use in therapy, particularly for use in the treatment of cancer. The present invention also relates to methods of treating cancer comprising the administration of a compound of Formula (I) to a subject in need thereof, and to pharmaceutical compositions and kits comprising such compounds.
Type:
Grant
Filed:
February 3, 2020
Date of Patent:
April 23, 2024
Assignee:
HEMISPHERIAN AS
Inventors:
Adam Brian Robertson, Terezia Prikrylova
Abstract: Minimally invasive treatment methods for benign prostatic hyperplasia (BPH) tissue. A system includes a sustained release formulation comprising a cytostatic or cytotoxic drug, and an applicator or delivery system for local delivery of a composition comprising or consisting essentially of the sustained release formulation to the prostate. The applicator containing the composition is characterized by a KIR value of between 40 and 400 Centipoise per unit area.
Type:
Grant
Filed:
December 6, 2022
Date of Patent:
April 16, 2024
Inventors:
Olof Mikael Trollsas, John J. Stankus, Shahram Shawn Gholami
Abstract: The invention provides methods of modulating and regulating NHD protein-protein interactions through nicotinamide mononucleotide, analogs and derivatives thereof, such as NAD+. Such modulation may be useful in methods of treating and preventing cancer, aging, cell death, radiation damage, radiation exposure, among others, may improve DNA repair, cell proliferation, cell survival, among others, and may increase the life span of a cell or protect it against certain stresses, among others.
Type:
Grant
Filed:
May 5, 2022
Date of Patent:
April 16, 2024
Assignees:
President and Fellows of Harvard College, Metro International Biotech, LLC
Inventors:
David A. Sinclair, Jun Li, Karl D. Normington
Abstract: An object of the present invention is to provide a new means for treating or ameliorating a blood cancer patient, wherein the new means has high effect and few side effects. The present invention relates to a combined medicine for use in a method for treating or ameliorating a blood cancer patient, comprising 4-amino-1-(2-cyano-2-deoxy-?-D-arabinofuranosyl)-2(1H)-pyrimidinone or a salt thereof and venetoclax or a salt thereof.
Abstract: The invention relates to a process for isolating nucleic acids, such as DNA and RNA, using a non-alcoholic and non-chaotropic binding solution, and to the binding solutions and kits suitable for such a process.
Abstract: The invention relates to compounds and compositions for modulation of nicotinamide adenine dinucleotide (NAD+). The invention also relates to methods of making such compounds and compositions. The invention relates to pharmaceutical compositions containing one or more NAD+ modulating compounds as a first ingredient in combination with one or more active pharmaceutical ingredients. Further, the invention relates to methods of using such compounds or compositions to promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD+) in cells and tissues for treating diseases and/or improving cell and tissue survival.
Type:
Grant
Filed:
March 18, 2020
Date of Patent:
March 26, 2024
Assignee:
Metro International Biotech, LLC
Inventors:
Bruce Szczepankiewicz, James M. McKearin
Abstract: The present invention relates to novel methods for treating or preventing coronavirus infection and cytokine-associated toxicity, including cytokine toxicity resulting from aberrant activation of the immune system in coronavirus disease or infection, such as those from SARS-CoV-2.
Abstract: Methods for the prevention or treatment of Alzheimer's disease in a human patient are disclosed comprising administering a hydroxypropyl-beta-cyclodextrin.
Type:
Grant
Filed:
October 24, 2019
Date of Patent:
March 12, 2024
Assignee:
Cyclo Therapeutics, Inc.
Inventors:
Sharon H. Hrynkow, Jeffrey L. Tate, N. Scott Fine
Abstract: The present invention relates to an antiviral application of nucleoside analogs. Specifically, the present invention relates to uses of nucleoside analogs and a pharmaceutical composition thereof as: (a) inhibitors for inhibiting the replication of coronaviruses, influenza viruses, respiratory syncytial viruses, flaviviridae viruses, filoviridae viruses and/or porcine epidemic diarrhea virus (PEDV); and/or (b) medicines for treating and/or preventing and mitigating diseases caused by coronavirus, influenza virus, respiratory syncytial virus, flaviviridae virus, filoviridae virus and/or porcine epidemic diarrhea virus (PEDV) infections. The nucleoside analogs according to the invention may treat and/or prevent and mitigate respiratory infection, pneumonia (COVID-19) and other related diseases caused by 2019 novel coronavirus infection.
Type:
Grant
Filed:
April 16, 2021
Date of Patent:
March 5, 2024
Assignees:
Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Wuhan Institute of Virology, Chinese Academy of Science, Xinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Vigonvita Life Sciences Co., Ltd.
Inventors:
Yuanchao Xie, Gengfu Xiao, Yang He, Leike Zhang, Haji Akber Aisa, Hualiang Jiang, Jingshan Shen
Abstract: The present invention relates to a composition for preventing or treating a neuroinflammatory disease, which can inhibit the expression of neuroinflammatory cytokines, promote the degradation of amyloid beta, and improve a cognitive function in an animal model of Alzheimer's disease. More specifically, the present invention relates to a composition for preventing or treating a neuroinflammatory disease comprising didanosine or a pharmaceutically acceptable salt thereof, and the composition may be used for the development of drugs and quasi-drug materials.
Type:
Grant
Filed:
October 18, 2022
Date of Patent:
March 5, 2024
Assignees:
Daegu Gyeongbuk Institute of Science and Technology, GliaCellTech Inc.
Inventors:
Seong-Woon Yu, Hyeri Nam, Younghwan Lee
Abstract: The present disclosure provides a pharmaceutical composition comprising i) an A1 adenosine receptor (A1AR) agonist, ii) an A1AR antagonist, and iii) an anticholinergic. Kits utilizing i) an A1 adenosine receptor (A1AR) agonist, ii) an A1AR antagonist, and iii) an anticholinergic are also provided, as well as methods utilizing the described pharmaceutical compositions and kits.
Abstract: The present invention is directed to a palatable, hard chewable composition comprising a therapeutically effective amount of a veterinary acceptable isoxazoline, a stabilized macrocyclic lactone, an acceptable salt form of pyrantel, at least one natural animal based palatant, and at least one veterinary acceptable excipient; and methods for treating or preventing a parasitic infection or infestation in an animal in need thereof with said composition.
Abstract: The present disclosure is directed to methods of treating or preventing RNA virus infections and retroviral diseases, such as HIV and AIDS, comprising administering to a subject in need an effective amount of (a) a capsid inhibitor and (b) an adenosine derivative disclosed herein. Compositions comprising an effective amount of an adenosine derivative and an effective amount of a capsid (CA) inhibitor are also provided.
Abstract: An object of the present invention is to provide a combination drug containing cytarabine and a DHODH inhibitor, as a new anti-tumor agent, and to provide an anti-tumor effect enhancing agent which is used in combination with cytarabine, an anti-tumor kit, and an anti-tumor agent which is used in combination with cytarabine. According to the present invention, an anti-tumor agent and an anti-tumor kit containing cytarabine and a dihydroorotate dehydrogenase inhibitor compound are provided.
Abstract: A method produces a hairpin single-stranded RNA molecule capable of inhibiting expression of a target gene, including the step of reacting a first single-stranded oligo-RNA molecule represented by formula (I) with a second single-stranded oligo-RNA molecule represented by formula (II) in a mixed solvent including a buffer solution and a hydrophilic organic solvent in the presence of a dehydration condensation agent: 5?-Xc-Lx1 (I) and Lx2-X—Y-Ly-Yc-3? (II), wherein the dehydration condensation agent is selected from the group consisting of a triazine-based dehydration condensation agent, a uronium-based dehydration condensation agent including an N-hydroxy nitrogen-containing aromatic ring structure, a carbodiimide-based dehydration condensation agent, a 2-halopyridinium-based dehydration condensation agent, and a formamidinium-based dehydration condensation agent.
Abstract: The present invention relates novel 6-6 bicyclic aromatic ring substituted nucleoside analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
Type:
Grant
Filed:
March 9, 2022
Date of Patent:
January 30, 2024
Assignee:
Janssen Pharmaceutica NV
Inventors:
Tongfei Wu, Dirk Brehmer, Lijs Beke, An Boeckx, Gaston Stanislas Marcella Diels, Ronaldus Arnodus Hendrika Joseph Gilissen, Edward Charles Lawson, Vineet Pande, Marcus Cornelis Bernardus Catharina Paradé, Wim Bert Griet Schepens, Johannes Wilhelmus John F. Thuring, Marcel Viellevoye, Weimei Sun, Lieven Meerpoel
Abstract: The invention relates to compositions of nicotinamide mononucleotide derivatives and their methods of use. The invention also relates to methods of preparing nicotinamide mononucleotide derivatives. The invention relates to pharmaceutical compositions and nutritional supplements containing a nicotinamide mononucleotide derivative. The invention relates to methods of using nicotinamide mononucleotide derivatives that promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD+) in cells and tissues for treating diseases and improving cell and tissue survival.
Type:
Grant
Filed:
July 26, 2022
Date of Patent:
January 23, 2024
Assignee:
Metro International Biotech, LLC
Inventors:
Karl D. Normington, David A. Sinclair, David J. Livingston, James M. McKearin, Bruce Szczepankiewicz, Jonathan N. Kremsky